Pharmaceutical

Amylyx axes ALS drug from market after Phase III failure 

Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.

Apr 7, 2024 - 00:00
Amylyx axes ALS drug from market after Phase III failure 
Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.
Read the original article

Tags:

Previous Article

GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval

Next Article

England’s MMR vaccinations up 23% following NHS initiative

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news

STAT+: Pharmalittle: FDA approvals rebound, abortion pi...

Jan 4, 2024

STAT+: Sick patients collapsed waiting for care at Mass. hospital with known safety violations

STAT+: Sick patients collapsed waiting for care at Mass...

Feb 15, 2024

UK charities condemn continued drug shortages

UK charities condemn continued drug shortages

Apr 13, 2024